Low-Dose Testosterone for Women Over 65: What You Need to Know

Why Women Over 65 Are Asking About Testosterone

Testosterone is not just a male hormone. Women produce it throughout their lives, and it declines steadily well before menopause begins. By the time a woman reaches her mid-60s, her total testosterone level is roughly half what it was at age 20, and her free (bioavailable) testosterone is even lower because sex hormone-binding globulin tends to rise with age and with oral estrogen use.

Serum testosterone in women falls approximately 50% between ages 20 and 45, and continues to decline across the postmenopausal years. That trajectory matters clinically because low testosterone in women is associated with reduced sexual desire, persistent fatigue that does not resolve with adequate sleep, and changes in body composition including muscle mass and bone density.

Women over 65 face a specific clinical challenge: they often arrive at a menopause specialist or primary care clinician having already completed the transition through perimenopause, having tried or declined systemic hormone therapy, and carrying a list of symptoms that overlap with aging, depression, thyroid dysfunction, sleep disorders, and androgen insufficiency. Testosterone rarely gets mentioned first. That is a clinical gap worth naming directly.

What Happens to Testosterone Across the Female Life Span

Testosterone in women follows a curve that is almost invisible in standard gynecologic training. Peak levels occur in the early 20s. Levels decline through the 30s. The dramatic estrogen drop at menopause does not produce a simultaneous testosterone cliff, but the bilateral oophorectomy does, dropping androgen levels by roughly 50% overnight.

For a woman in her late 60s who had a natural menopause in her early 50s, testosterone has been declining for nearly two decades by the time she asks about it. That duration of low androgen exposure is one reason outcomes data for testosterone in women 65 and older are harder to interpret: we do not know how long deficiency has existed, and we do not have a validated serum threshold that defines insufficiency the way we do for estrogen.

The Evidence Gap Is Real and You Deserve to Hear It

The 2019 Global Consensus Position Statement on the Use of Testosterone Therapy for Women was signed by multiple major societies including the Endocrine Society, the British Menopause Society, and The Menopause Society (formerly NAMS). It explicitly states that most randomized controlled trials enrolled postmenopausal women primarily between ages 40 and 65. Women over 65 are underrepresented. The guideline endorses use for HSDD in postmenopausal women broadly but acknowledges that cardiovascular and breast safety data in older women specifically are not sufficient to make definitive long-term assurances.

This is not a reason to dismiss the therapy. It is a reason to make decisions with full information.

The One Indication With the Strongest Evidence: HSDD

Hypoactive sexual desire disorder is defined as persistently low sexual desire that causes personal distress. It is the indication for which testosterone in postmenopausal women has the most strong trial evidence, and it is the indication named in the 2019 Global Consensus Statement.

A 2019 systematic review and meta-analysis published in The Lancet Diabetes and Endocrinology analyzed 36 randomized trials enrolling 8,480 women and found that transdermal testosterone significantly improved sexual function scores, including desire, arousal, orgasm, and pleasure, compared with placebo. The effect size was meaningful for desire and arousal specifically.

What HSDD Looks Like at 65 and Beyond

At 65+, HSDD is frequently layered on top of genitourinary syndrome of menopause (GSM), relationship factors, partner health issues, chronic pain, and polypharmacy. SSRIs and SNRIs, which many older women take for depression or vasomotor symptoms, independently suppress sexual desire. Beta-blockers, antihistamines, and some blood pressure medications do the same.

Before attributing low desire solely to testosterone insufficiency, a thorough medication review matters. If a woman's desire was adequate before starting an SSRI two years ago and declined sharply afterward, the antidepressant is the likelier cause. If desire has been gradually fading for a decade regardless of medication changes, testosterone is a reasonable clinical consideration.

Scoring Desire Objectively

The Female Sexual Function Index (FSFI) and the Decreased Sexual Desire Screener (DSDS) are validated tools used in trials and clinical practice. A score on the FSFI desire subscale below 3.3 suggests clinically significant low desire. Asking your clinician to use a validated instrument gives the conversation a clinical anchor rather than leaving it to subjective impression.

Dosing in Women 65 and Older: Smaller Than You Think

The standard clinical target for women is a serum testosterone level within the physiologic range for premenopausal women, not the male range. That means roughly 10 to 55 ng/dL for total testosterone, depending on the assay used.

Typical transdermal doses in women run 150 to 300 micrograms per day, delivered via compounded cream, gel, or patch. There is no FDA-approved female testosterone product in the United States, which means all prescribing is off-label and all products are either compounded or used off-label from male-formulated products at fractionated doses.

Why the Dose Matters More in Older Women

Older women may have lower SHBG than younger postmenopausal women, particularly if they are not using oral estrogen. Lower SHBG means more free testosterone is available at a given total testosterone level. A compounded cream delivering 300 mcg/day may push free testosterone above the premenopausal range in a woman with low SHBG, producing androgenic side effects even when total testosterone looks normal.

This is why free testosterone measurement matters alongside total testosterone in women 65 and older, not just at initiation but at each monitoring interval.

Compounded vs. Male-Formulated Products

Most clinicians who prescribe testosterone to women use one of two approaches. First, a compounded transdermal preparation specifically formulated for women at 0.5 to 2% concentration, applied to the inner arm or thigh in volumes of 0.1 to 0.5 mL. Second, a male testosterone gel (1% or 1.62%) used at a fraction of the labeled dose.

Compounded preparations vary in bioavailability by pharmacy and formulation. The FDA has raised concerns about the consistency of compounded hormones, noting that potency, sterility, and absorption can differ substantially between compounding pharmacies. If you use a compounded product, choosing a pharmacy that follows USP 795 standards and performs third-party potency testing reduces, though does not eliminate, this variability.

Beyond Sexual Desire: What the Evidence Does and Does Not Support

Sexual desire is the only indication for which the evidence is strong enough to generate a consensus guideline recommendation. Several other outcomes are biologically plausible and studied, but the data are more limited, particularly in women over 65.

Muscle Mass and Physical Function

Testosterone has anabolic effects on skeletal muscle in women, and sarcopenia (age-related muscle loss) accelerates after menopause. Small trials suggest that testosterone supplementation may attenuate lean mass loss and improve muscle strength in postmenopausal women. However, no large randomized trial has established a functional benefit in women over 65 specifically, and physical activity remains the most evidence-supported intervention for sarcopenia in this age group.

Bone Density

Androgens stimulate bone formation directly, and testosterone is converted to estradiol in bone tissue via aromatization. A 2018 placebo-controlled trial published in JCEM found that testosterone implants improved bone mineral density at the hip and spine in postmenopausal women not using estrogen. The clinical relevance for women already on bisphosphonates or denosumab is unclear.

Cognition and Mood

The relationship between testosterone and cognitive function in older women is among the least settled questions in women's hormonal health. Observational data are inconsistent, and no adequately powered randomized trial has demonstrated a protective effect on dementia or cognitive decline in women 65 and older using physiologic testosterone doses. Mood improvements noted in HSDD trials may be secondary to improved sexual function rather than a direct androgenic effect.

Safety Considerations Specific to Women Over 65

The following framework reflects how safety signals cluster differently in women 65 and older compared with younger postmenopausal women, based on known pharmacology and available trial data.

Cardiovascular Risk

Older women carry higher baseline cardiovascular risk than younger postmenopausal women, and any hormonal therapy in this group warrants careful individual risk assessment. Supraphysiologic testosterone levels (above the premenopausal female range) are associated with unfavorable lipid changes, including reduced HDL cholesterol. The 2019 Global Consensus Statement notes that when testosterone is maintained within the female physiologic range, the available data do not show an adverse cardiovascular signal, but this reassurance is based on trials of relatively short duration (typically 6 to 24 months) in women younger than 65 predominantly.

For a woman over 65 with established coronary artery disease, a history of stroke, or uncontrolled hypertension, the cardiovascular question is not answered by available data, and an individualized risk-benefit conversation with her cardiologist is appropriate before starting testosterone.

Breast Cancer Risk

The 2019 Global Consensus Statement states explicitly that "there is no evidence that testosterone therapy increases the risk of breast cancer" based on current trial data. However, the same document notes that long-term data are insufficient and that women with hormone-receptor-positive breast cancer should avoid testosterone therapy outside of specialist-supervised clinical trials. A woman over 65 with a personal history of breast cancer should discuss this with her oncologist before proceeding.

Polycythemia

Testosterone stimulates red blood cell production. In men using testosterone therapy, polycythemia is a recognized and monitored risk. In women using physiologic female-range doses, the risk is substantially lower, but hematocrit should still be checked at baseline and at 3 to 6 months. This is especially relevant in women over 65 who may have conditions that independently raise red cell mass.

Androgenic Side Effects

Excess hair growth (hirsutism), acne, clitoral enlargement, and voice deepening can occur if testosterone levels exceed the premenopausal female range. In women 65 and older, SHBG may be lower, increasing susceptibility to androgenic effects at a given dose. Monitoring free testosterone and adjusting dose accordingly is the practical safeguard.

Monitoring Schedule for Women 65 and Older on Testosterone

A reasonable monitoring schedule, consistent with the approach recommended in the 2019 Global Consensus Statement, looks like this:

• Baseline: Total testosterone, free testosterone (equilibrium dialysis method preferred), SHBG, hematocrit, fasting lipids, and a validated sexual function questionnaire score
• 3 months: Total and free testosterone, hematocrit, side-effect review
• 6 months: Full labs repeated, lipids included, FSFI or equivalent re-administered
• Annually thereafter: Same panel, plus breast health review and cardiovascular risk reassessment

The goal at each lab check is to confirm total testosterone remains within the premenopausal female reference range (approximately 10 to 55 ng/dL, assay-dependent) and that free testosterone has not exceeded that range. If free testosterone is consistently above the premenopausal ceiling, the dose needs reduction regardless of whether the patient is experiencing side effects.

Pregnancy, Lactation, and Contraception

Women 65 and older are postmenopausal. Pregnancy is not physiologically possible without assisted reproductive technology using donor eggs, and this section applies to the rare clinical context where that applies or where this information is relevant for clinical completeness.

Testosterone is an absolute contraindication in pregnancy at any age. Testosterone is an FDA Pregnancy Category X medication: animal and human data demonstrate fetal harm, including virilization of female fetuses. No dose is considered safe during pregnancy.

Testosterone transfers into breast milk. Lactation is not applicable for women 65 and older. For completeness: any premenopausal or perimenopausal woman being considered for testosterone off-label who could become pregnant must use reliable non-hormonal or barrier contraception, or have confirmed surgical sterility, before starting therapy.

For postmenopausal women of any age, including 65 and older: if you are using estrogen-only hormone therapy without a uterus, or combined estrogen-progestogen therapy with a uterus, testosterone does not change your contraception requirements because you are not at pregnancy risk. If you are in early perimenopause and your clinician is considering testosterone, confirmed postmenopausal status or reliable contraception is the clinical requirement.

Who This Is Right For (and Who Should Pause)

Women Over 65 Who May Benefit

• Postmenopausal women with confirmed low sexual desire causing personal distress (HSDD), after ruling out relationship, medication, and psychological contributors
• Women whose HSDD has not responded adequately to systemic estrogen therapy alone
• Women interested in a time-limited trial with monitoring and a clear stopping plan if no benefit at 6 months

Women Over 65 Who Should Approach With Caution or Seek Specialist Input

• Women with hormone-receptor-positive breast cancer history (discuss with oncology first)
• Women with established cardiovascular disease, uncontrolled hypertension, or recent thrombotic events
• Women with polycythemia or high baseline hematocrit
• Women on anticoagulants (testosterone may alter clotting parameters)
• Women with androgenic skin conditions already managed by dermatology (acne, hirsutism)

A Note on "Anti-Aging" and Wellness Clinic Marketing

A meaningful portion of testosterone prescriptions for older women originate from concierge or wellness clinics that frame testosterone as an anti-aging therapy addressing fatigue, brain fog, weight gain, and libido simultaneously. The evidence does not support using testosterone for all these purposes simultaneously in women 65 and older. Fatigue in an older woman has a long differential, including hypothyroidism, anemia, sleep apnea, depression, and medication effects, none of which testosterone addresses. Using a validated indication with clear monitoring is meaningfully different from a blanket anti-aging protocol.

Transitioning to Care for Women 65 and Older: What Providers Should Know

Many women over 65 who ask about testosterone have been managing their own hormonal health through perimenopause and early menopause with one clinician and are now transitioning care: a move to a new city, a provider retirement, or a shift from OB-GYN to internal medicine or geriatrics as primary care.

That transition is where testosterone management frequently falls through the gaps. Internists and geriatricians receive little training in women's androgen physiology. Gynecologists who retire or leave a practice may not document testosterone use in a way that a receiving internist knows how to continue.

The Menopause Society (formerly NAMS) recommends that clinicians managing postmenopausal hormonal therapies maintain a current medication list that includes compounded preparations, which are often omitted from pharmacy records because they are not filled at retail pharmacies. If you are transferring care, bring the following to your first appointment with a new clinician:

• The name and contact of your compounding pharmacy
• Your most recent testosterone labs (total and free) with the collection date
• The dose and formulation you use, written out (e.g., "testosterone 2% cream, 0.2 mL applied to inner arm daily")
• Your last FSFI or symptom score if you have one documented

A new clinician who has not managed testosterone in women before may be willing to continue a stable, well-monitored regimen if the documentation is clear. An undocumented compounded prescription with no recent labs is a reasonable reason for a new provider to pause the prescription pending a proper reassessment.

Frequently Asked Questions